ATE237339T1 - Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen - Google Patents

Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen

Info

Publication number
ATE237339T1
ATE237339T1 AT97935400T AT97935400T ATE237339T1 AT E237339 T1 ATE237339 T1 AT E237339T1 AT 97935400 T AT97935400 T AT 97935400T AT 97935400 T AT97935400 T AT 97935400T AT E237339 T1 ATE237339 T1 AT E237339T1
Authority
AT
Austria
Prior art keywords
blood
autoimmune diseases
modified
aliquot
treat autoimmune
Prior art date
Application number
AT97935400T
Other languages
English (en)
Inventor
Anthony E Bolton
Original Assignee
Vasogen Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9617611.0A external-priority patent/GB9617611D0/en
Application filed by Vasogen Ireland Ltd filed Critical Vasogen Ireland Ltd
Application granted granted Critical
Publication of ATE237339T1 publication Critical patent/ATE237339T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/40—Peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/10—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person
    • A61K41/17—Inactivation or decontamination of a medicinal preparation prior to administration to an animal or a person by ultraviolet [UV] or infrared [IR] light, X-rays or gamma rays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/36—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits
    • A61M1/3681—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation
    • A61M1/3683—Other treatment of blood in a by-pass of the natural circulatory system, e.g. temperature adaptation, irradiation ; Extra-corporeal blood circuits by irradiation using photoactive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M1/00—Suction or pumping devices for medical purposes; Devices for carrying-off, for treatment of, or for carrying-over, body-liquids; Drainage systems
    • A61M1/14—Dialysis systems; Artificial kidneys; Blood oxygenators ; Reciprocating systems for treatment of body fluids, e.g. single needle systems for hemofiltration or pheresis
    • A61M1/32—Oxygenators without membranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0216—Ozone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2202/00—Special media to be introduced, removed or treated
    • A61M2202/02—Gases
    • A61M2202/0266—Nitrogen (N)
    • A61M2202/0275—Nitric oxide [NO]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M2205/00—General characteristics of the apparatus
    • A61M2205/05—General characteristics of the apparatus combined with other kinds of therapy
    • A61M2205/051—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy
    • A61M2205/053—General characteristics of the apparatus combined with other kinds of therapy with radiation therapy ultraviolet
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S424/00—Drug, bio-affecting and body treating compositions
    • Y10S424/81—Drug, bio-affecting and body treating compositions involving autoimmunity, allergy, immediate hypersensitivity, delayed hypersensitivity, immunosuppression, immunotolerance, or anergy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Anesthesiology (AREA)
  • Cardiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Inorganic Chemistry (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AT97935400T 1996-08-22 1997-08-11 Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen ATE237339T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB9617611.0A GB9617611D0 (en) 1996-08-22 1996-08-22 Treatment of autoimmune disease
US08/754,348 US5980954A (en) 1992-02-07 1996-11-22 Treatment of autoimmune diseases
PCT/CA1997/000564 WO1998007436A1 (en) 1996-08-22 1997-08-11 Treatment of autoimmune diseases

Publications (1)

Publication Number Publication Date
ATE237339T1 true ATE237339T1 (de) 2003-05-15

Family

ID=26309905

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97935400T ATE237339T1 (de) 1996-08-22 1997-08-11 Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen

Country Status (12)

Country Link
US (2) US5980954A (de)
EP (1) EP0920322B9 (de)
JP (1) JP3883013B2 (de)
AT (1) ATE237339T1 (de)
AU (1) AU724265B2 (de)
CA (1) CA2263911C (de)
DE (1) DE69721006T2 (de)
DK (1) DK0920322T3 (de)
ES (1) ES2199367T3 (de)
NZ (1) NZ334635A (de)
PT (1) PT920322E (de)
WO (1) WO1998007436A1 (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
GB9617611D0 (en) * 1996-08-22 1996-10-02 Vasogen Inc Treatment of autoimmune disease
US6669965B2 (en) * 1992-02-07 2003-12-30 Vasogen Ireland Limited Method of treating atherosclerosis
US6066489A (en) 1996-08-30 2000-05-23 Arrow International, Inc. Method for treating blood borne viral pathogens such as immunodeficiency virus
CA2206180A1 (en) * 1997-05-27 1998-11-27 Vasogen Inc. Treatment of chronic post-traumatic pain syndromes
AU741181B2 (en) * 1997-09-12 2001-11-22 Centre De Recherche Du Centre Hospitalier De L'universite De Montreal Treatment of stress and preconditioning against stress
CA2244554A1 (en) * 1998-07-30 2000-01-30 Vasogen Inc. Inhibition of graft versus host disease
JP2002529510A (ja) * 1998-11-13 2002-09-10 バソジェン アイルランド リミテッド 哺乳動物においてアテローム性動脈硬化症を予防および退行させるための方法
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals
NZ512849A (en) * 1999-01-12 2003-02-28 Ct De Rech Du Ct Hospitalier D Pre-conditioning against cell death
CA2269364A1 (en) * 1999-04-19 2000-10-19 Vasogen Ireland Limited Treatment of inflammatory and allergic disorders
CA2271190A1 (en) * 1999-05-06 2000-11-06 Vasogen Ireland Limited Improved method for treating mammals with modified mammalian blood
PT1214037E (pt) * 1999-09-16 2004-08-31 Vasogen Ireland Ltd Aparelho e processo para o condicionamento de sangue de mamiferos
US7125897B1 (en) * 1999-09-24 2006-10-24 Vasogen Ireland Limited Combined therapies for atherosclerosis treatment
CA2296997A1 (en) * 2000-01-18 2001-07-18 Vasogen Ireland Limited Treatment of congestive heart failure
CA2297448A1 (en) * 2000-01-28 2001-07-28 Vasogen Inc. Improved inhibition of graft versus host disease
US6800300B1 (en) 2000-03-31 2004-10-05 Vasogen Ireland Limited Method for treating autoimmune and alloimmune diseases
AU2001251612A1 (en) * 2000-04-14 2001-10-30 Millennium Pharmaceuticals, Inc. Roles of jak/stat family members in tolerance induction
US6970740B2 (en) * 2000-04-19 2005-11-29 Clemson University UVC rediation therapy for leukemia
WO2001080939A2 (en) * 2000-04-19 2001-11-01 Clemson University Uvc radiation therapy for chronic lymphocytic leukemia
CA2308105A1 (en) * 2000-05-11 2001-11-11 Vasogen Ireland Limited Treatment of il-10 deficiencies
CA2309424A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of neurodegenerative and other neurological disorders
CA2309417A1 (en) * 2000-05-25 2001-11-25 Anthony E. Bolton Apoptotic entities for use in treatment of endothelium dysfunction disorders
CA2309518A1 (en) * 2000-05-25 2001-11-25 Vasogen Ireland Limited Apoptotic entities for use in treatment of t-cell-mediated and inflammatory disorders
CA2324199A1 (en) 2000-10-25 2002-04-25 Vasogen Ireland Limited Chronic lymphocytic leukemia treatment
CA2327630A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Transforming growth factor regulation
CA2327631A1 (en) * 2000-12-05 2002-06-05 Vasogen Ireland Limited Inflammatory cytokine secretion inhibition
US20020090360A1 (en) * 2000-12-05 2002-07-11 Bolton Anthony E. Inflammatory cytokine secretion inhibition
CA2333494A1 (en) * 2001-02-01 2002-08-01 Vasogen Ireland Limited Blood brain barrier modulation
US7122208B2 (en) * 2001-04-06 2006-10-17 Vasogen Ireland Limited Compositions containing apoptotic entities
CA2468197A1 (en) * 2001-11-29 2003-06-05 Therakos, Inc. Methods for pretreating a subject with extracorporeal photopheresis and/or apoptotic cells
MXPA04009897A (es) * 2002-04-10 2004-12-07 Vasogen Ireland Ltd Aspectos electrocardiograficos del tratamiento de la insuficiencia cardiaca congestiva (chf).
JP3927922B2 (ja) * 2003-05-21 2007-06-13 Ｙｋｋ株式会社 スライドファスナー用スプリング体及び同スプリング体が装着されたスライダー
US9557325B2 (en) * 2003-06-09 2017-01-31 Redox-Reactive Reagents Llc Method of altering the binding specificity of proteins by oxidation-reduction reactions
US7892751B2 (en) * 2003-06-09 2011-02-22 Redox-Reactive Reagents Llc Method of detecting or diagnosing of a neurodegenerative disease or condition
AU2004248155B2 (en) * 2003-06-09 2008-10-23 Redox-Reactive Reagents L.L.C. Method of altering the binding specificity of plasma proteins by oxidation-reduction reactions
US20100318014A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of acute ischemic brain stroke with ozone
US20100316730A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of cardiovascular diseases with ozone
US20100316727A1 (en) * 2003-07-31 2010-12-16 Latino Joseph S Treatment of inflammatory disorders with ozone
US7736494B2 (en) * 2003-07-31 2010-06-15 Acquisci, Inc. Ozone delivery system including a variable pitch gas-fluid contact device
US20050051497A1 (en) * 2003-07-31 2005-03-10 Latino Joseph S. Viral inactivation using ozone
US20050189302A1 (en) * 2003-07-31 2005-09-01 Latino Joseph S. Viral inactivation using ozone
HUE040595T2 (hu) * 2004-04-02 2019-03-28 Swedish Orphan Biovitrum Ab Publ Eljárás IL-1ra aggregációjának csökkentésére
EP1768662A2 (de) * 2004-06-24 2007-04-04 Novartis Vaccines and Diagnostics, Inc. Immunstimulatoren kleiner moleküle und assays für deren nachweis
EP1773360A4 (de) * 2004-07-20 2009-09-02 Vasogen Ireland Ltd Behandlung von akuten entzündlichen zuständen
US20060210644A1 (en) * 2004-12-16 2006-09-21 Bruce Levin Materials, methods, and devices for treatment of arthropathies and spondylopathies
US20090232834A1 (en) * 2005-07-18 2009-09-17 Al-Harbi Saleh A Methods and Agents to Treat Autoimmune Diseases
WO2008124096A1 (en) * 2007-04-04 2008-10-16 Gaia Medical Institute Systems and methods for analyzing persistent homeostatic perturbations
US9358292B2 (en) 2007-04-08 2016-06-07 Immunolight, Llc Methods and systems for treating cell proliferation disorders
US8951561B2 (en) 2007-08-06 2015-02-10 Duke University Methods and systems for treating cell proliferation disorders using plasmonics enhanced photospectral therapy (PEPST) and exciton-plasmon enhanced phototherapy (EPEP)
US20090104212A1 (en) * 2007-08-06 2009-04-23 Immunolight Methods and systems for treating cell proliferation disorders using two-photon simultaneous absorption
KR101322247B1 (ko) * 2007-09-06 2013-10-25 삼성전자주식회사 진공청소기용 흡입브러시 및 그 높이조절방법
WO2013009688A1 (en) 2011-07-08 2013-01-17 Bourke Frederic A Phosphors and scintillators for light stimulation within a medium
EP2268311A4 (de) 2008-04-04 2014-08-27 Immunolight Llc Nicht-invasive systeme und verfahren zur photobiomodulation in situ
ITMI20131667A1 (it) * 2013-10-09 2015-04-10 Ind Paolo Gobbi Frattini Metodo per pre-trattare le cellule ematiche prima della separazione.
WO2015112850A2 (en) 2014-01-23 2015-07-30 Wenle Xia Use of psoralen derivatives and combination therapy for treatment of cell proliferation disorders
EP3157519B1 (de) 2014-06-19 2021-05-12 Immunolight, LLC Verfahren und systeme zur behandlung von zellproliferationskrankheiten mit psoralenderivaten

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1068428C2 (de) 1957-05-21 1960-04-21 Hermann Dr Med Jentjens Verfahren und Einrichtung zur Herstellung von oxygeniertrm Blut
US3715430A (en) * 1969-08-04 1973-02-06 E Ryan Purified oxygen gas containing ozone and higher oxygen polymers
US3925344A (en) 1973-04-11 1975-12-09 Community Blood Council Plasma protein substitute
US4061736A (en) 1975-02-02 1977-12-06 Alza Corporation Pharmaceutically acceptable intramolecularly cross-linked, stromal-free hemoglobin
US4473496A (en) 1981-09-14 1984-09-25 The United States Of America As Represented By The Secretary Of The Army Intramolecularly crosslinked hemoglobin
JPS58198466A (ja) 1982-05-12 1983-11-18 Teijin Ltd ５−チアプロスタグランジン類およびその製造法
FR2528848A1 (fr) 1982-06-16 1983-12-23 Sanofi Sa Nouveau derive de thieno-pyridone, son procede de preparation et son application therapeutique
US4613322A (en) * 1982-12-08 1986-09-23 Edelson Richard Leslie Method and system for externally treating the blood
US4529719A (en) 1983-05-04 1985-07-16 Tye Ross W Modified crosslinked stroma-free tetrameric hemoglobin
US4695647A (en) 1984-03-22 1987-09-22 Drug Science Foundation Aromatic derivatives of 13-azaprostanoic acid
US4659726A (en) 1984-04-19 1987-04-21 Kanebo, Ltd. Novel 4,5-Bis (4-methoxyphenyl)-2-(pyrrol-2-yl) thiazoles and pharmaceutical composition containing the same
US4600531A (en) 1984-06-27 1986-07-15 University Of Iowa Research Foundation Production of alpha-alpha cross-linked hemoglobins in high yield
DD249143A3 (de) * 1985-03-20 1987-09-02 Ilmenau Tech Hochschule Vorrichtung zur physiologisch-therapeutisch wirksamen optischen bestrahlung koerpereigenen venenblutes
US4584130A (en) 1985-03-29 1986-04-22 University Of Maryland Intramolecularly cross-linked hemoglobin and method of preparation
US4632980A (en) * 1985-04-03 1986-12-30 Immunologics Ozone decontamination of blood and blood products
US4826811A (en) 1986-06-20 1989-05-02 Northfield Laboratories, Inc. Acellular red blood cell substitute
US5194590A (en) 1986-06-20 1993-03-16 Northfield Laboratories, Inc. Acellular red blood cell substitute
DE8704467U1 (de) * 1987-01-15 1988-05-26 Quarzlampenfabrik Dr.-Ing. Felix W. Müller GmbH & Co KG, 45239 Essen Gerät zur Herstellung von oxygeniertem Blut
US4838852A (en) * 1987-03-27 1989-06-13 Therakos, Inc. Active specific immune suppression
GB8710598D0 (en) 1987-05-05 1987-06-10 Star Medical Diagnostics Ltd Hemoglobin based blood substitute
GB8711614D0 (en) 1987-05-16 1987-06-24 Medical Res Council Proteins
DE68921912D1 (de) * 1988-04-29 1995-05-04 Medizone Int Inc Vorrichtung für die gesteuerte Generierung und Verabreichung von Ozon.
US4983637A (en) 1988-06-24 1991-01-08 Stephen Herman Method for treating viral infection of HIV
WO1992010198A1 (en) * 1990-12-06 1992-06-25 Johnson & Johnson Research Pty Limited Immunotherapeutic agents, compositions and methods
US5250665A (en) 1991-05-31 1993-10-05 The University Of Toronto Innovations Foundation Specifically β-β cross-linked hemoglobins and method of preparation
US5980954A (en) 1992-02-07 1999-11-09 Vasogen Ireland Limited Treatment of autoimmune diseases
DE69334101T2 (de) 1992-02-07 2007-10-04 Vasogen Ireland Ltd., Shannon Verwendung von Blut mit erhöhter Stickoxidkonzentration zur Herstellung eines Medikaments
WO1993015778A1 (en) 1992-02-07 1993-08-19 Anthony Ernest Bolton Method of inhibiting the aggregation of blood platelets
US5591457A (en) 1992-02-07 1997-01-07 Vasogen Inc Method of inhibiting the aggregation of blood platelets and stimulating the immune systems of a human
JPH10506636A (ja) 1995-05-05 1998-06-30 バソゲン・インコーポレーテッド 内皮ライニング効果及び血管痙攣性疾患の治療
US6264646B1 (en) 1998-11-13 2001-07-24 Vasogen Ireland Limited Method for preventing and reversing atherosclerosis in mammals

Also Published As

Publication number Publication date
AU3844297A (en) 1998-03-06
NZ334635A (en) 2000-08-25
JP2000517302A (ja) 2000-12-26
AU724265B2 (en) 2000-09-14
EP0920322B1 (de) 2003-04-16
PT920322E (pt) 2003-11-28
EP0920322A1 (de) 1999-06-09
DK0920322T3 (da) 2003-08-04
JP3883013B2 (ja) 2007-02-21
CA2263911A1 (en) 1998-02-26
EP0920322B9 (de) 2003-10-29
US5980954A (en) 1999-11-09
ES2199367T3 (es) 2004-02-16
WO1998007436A1 (en) 1998-02-26
DE69721006D1 (de) 2003-05-22
US6569467B1 (en) 2003-05-27
DE69721006T2 (de) 2004-01-22
CA2263911C (en) 2007-01-16

Similar Documents

Publication Publication Date Title
ATE237339T1 (de) Verwendung des modifizierten eigenen blutes zur behandlung von autoimmunerkrankungen
ATE262336T1 (de) Verwendung von 9-desoxy-2',9-alpha-methano-3-oxa- 4,5,6-trinor-3,7-(1',3'-interphenylen)-13,14- dihydroprostaglandin-f1 zur behandlung von peripheren vaskulären erkrankungen
ES2000428A4 (es) Procedimiento para producir un medicamento para el tratamiento de la enfermedad de alzheimer, que contiene galantamina, y dispositivo medico correspondiente.
ATE88097T1 (de) Verfahren und system zur entfernung von immunosuppressiven bestandteilen aus saeugetierblut.
DE3684363D1 (de) Phosphonylmethoxyalkyl-adeninen zur behandlung von viruskrankheiten.
CY1105818T1 (el) Χρησεις του et743 στην θepαπευτικη αγωγη του καρκινου
MXPA03006771A (es) Anticuerpos modificados y metodos de uso.
EP0787802A3 (de)
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
KR950700079A (ko) 이식체-대-숙주 질환을 억제하기 위한 인터루킨-10의 용도(Use of interleukin-10 to suppress graft-vs. -host disease)
DE3685853D1 (de) Mittel zur behandlung von knochenkrankheiten.
NO913129D0 (no) Nytt trombolytisk middel.
ATE366581T1 (de) Apoptotische körper zur verwendung in der behandlung von neurodegenerativen und sonstigen nervenerkrankungen
NO893135L (no) Fremgangsmaate for fremstilling av n-2,3-butadienyl tri- og tetraaminoalkanderivater.
ATE246929T1 (de) Wirkungen auf der endothelauskleidung und behandlung von vasospastischen erkrankungen
DE69634859D1 (de) Induktion von immunologischer toleranz
DK137589A (da) Salicylsyreholdigt middel til behandling af hudsygdomme
ATA113492A (de) Mehrfachbeutelsystem zur sterilen behandlung von menschlichen blutkonserven
GB9617611D0 (en) Treatment of autoimmune disease
RU94022481A (ru) Способ определения иммуногенной активности биоактивных соединений и состав для его осуществления
SU833247A1 (ru) Способ лечени заболеваний,вызван-НыХ уКуСОМ КлЕщЕй
Grant DUHIKYA: THE HOPI HEALER.
ATE72397T1 (de) Pharmazeutische zusammensetzungen zur behandlung von hyperproliferativer hautkrankheit.
UA37041A (uk) Спосіб стимуляції функціональної активності т-лімфоцитів
DE69218544D1 (de) Verwendung von BMY 14802 zur Behandlung von Angstzuständen bei Patienten mit Benzodiazepin-Entzugserscheinungen

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0920322

Country of ref document: EP

REN Ceased due to non-payment of the annual fee